ZX-101A

DRUG3 trials

Sponsors

Hangzhou Zenshine Pharmaceuticals Co., Ltd., Nanjing Zenshine Pharmaceuticals

Conditions

Advanced Solid TumorCLL/SLLChronic Lymphocytic LeukemiaNon Hodgkin LymphomaNon-hodgkin LymphomaPeripheral T Cell LymphomaSmall Lymphocytic Lymphoma

Phase 1

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

TerminatedNCT04504708

Hangzhou Zenshine Pharmaceuticals Co., Ltd.Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma, Small Lymphocytic Lymphoma

Start: 2021-02-17End: 2022-07-08Updated: 2022-10-21

A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors

Nanjing Zenshine PharmaceuticalsAdvanced Solid Tumor

Start: 2022-03-09End: 2024-04-30Target: 76Updated: 2022-03-14

A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

CompletedNCT05269940

Nanjing Zenshine PharmaceuticalsCLL/SLL, Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma

Start: 2022-02-17End: 2024-07-05Updated: 2024-11-13

Related Papers

Abstract CT526: A Phase 1/2a Study of a PI3Kδγ dual inhibitor ZX-101A in patients with advanced solid tumors

Cancer Research2022-06-15

Abstract CT202: A phase 1/2a, dose-escalation and dose-expansion study of ZX-101A in patients with relapsed/resistant or refractory advanced hematologic malignancies

Cancer Research2021-07-01